Bipolar Disorder

Bipolar Disorder is a chronic mood disorder characterised by recurrent episodes of mania or hypomania alternating with depressive episodes, causing significant impairment in social and occupational functioning. DSM-5-TR recognises Bipolar I Disorder (defined by at least one manic episode), Bipolar II Disorder (hypomanic and major depressive episodes, never a full manic episode), and Cyclothymic Disorder (numerous subthreshold mood swings for >=2 years). References: DSM-5-TR, StatPearls (NCBI Bookshelf).

Bipolar Disorder is a chronic mood disorder characterised by recurrent episodes of mania or hypomania alternating with depressive episodes, causing significant impairment in social and occupational functioning. DSM-5-TR recognises Bipolar I Disorder (defined by at least one manic episode), Bipolar II Disorder (hypomanic and major depressive episodes, never a full manic episode), and Cyclothymic Disorder (numerous subthreshold mood swings for >=2 years). Bipolar disorder is a leading cause of global disability, affecting ~2-4% of the population. It is associated with high rates of suicide, comorbid disorders, and functional impairment. Accurate diagnosis is critical because antidepressant monotherapy can precipitate mania. This information is for psychoeducation only.

Manic episode (>=1 week, or any duration if hospitalised or psychotic): Abnormally and persistently elevated, expansive, or irritable mood and increased goal-directed activity/energy, plus >=3 (or 4 if mood is only irritable) of: grandiosity/inflated self-esteem; decreased need for sleep; pressured/increased talkativeness; racing thoughts/flight of ideas; distractibility; increased goal-directed activity or psychomotor agitation; impulsive high-risk behaviour (spending, sexual, investments, reckless driving). Hypomanic episode: Same symptoms, duration >=4 days, no hospitalisation, no psychosis, no marked impairment. Major depressive episode: as per MDD criteria (see MDD document). Mixed features specifier: symptoms of opposite polarity present during a mood episode. Rapid cycling: >=4 mood episodes in 12 months. Psychotic features (delusions, hallucinations) may occur in mania or severe depression.

Genetic: heritability is among the highest in psychiatry (~80-90% in Bipolar I from twin studies). First-degree relatives have ~10x increased risk. Bipolar disorder and schizophrenia share genetic risk variants. Candidate genes: CACNA1C, ANK3, TRANK1; multiple risk loci from GWAS. Neurobiological: circadian rhythm disruption (life events disrupting sleep/wake cycles can trigger episodes - social zeitgeber theory); HPA axis dysregulation; mitochondrial dysfunction implicated. Environmental triggers: psychosocial stress and disrupted sleep schedules (especially for mania); antidepressant use without mood stabiliser; stimulant/substance use; childbirth (postpartum mania/psychosis).

Medical: multiple sclerosis, thyroid disorders, and certain medications (steroids, antidepressants, stimulants) can trigger bipolar-spectrum episodes.

Bipolar disorder arises from complex interactions between genetic vulnerability, neurobiological dysregulation, and environmental triggers. Monoamine dysregulation: dopamine excess (mania) and deficiency (depression); serotonin and norepinephrine fluctuations across phases. Second messenger systems: dysregulation of phosphoinositide (IP3/DAG), PKC, GSK-3beta signalling pathways; lithium acts on multiple second messenger pathways. Mitochondrial dysfunction and oxidative stress have been demonstrated. Circadian clock genes (CLOCK, ARNTL/BMAL1) are implicated in episode timing and vulnerability. Neuroinflammation: elevated cytokines especially during acute episodes. Neuroplasticity: progressive brain changes with repeated episodes (amygdala enlargement, prefrontal thinning). Social Zeitgeber Theory: disruptions in daily routines/social rhythms destabilise circadian rhythms and trigger mood episodes.

Global prevalence: Bipolar I ~1%, Bipolar II ~1.1%, cyclothymia ~0.4-1%; bipolar spectrum ~2-4%. Equal sex distribution for Bipolar I; Bipolar II more commonly diagnosed in women. Median age of onset: 18-22 years; onset before age 18 (paediatric bipolar) is recognised but controversial. Average diagnostic delay: 5-10 years, often initially misdiagnosed as MDD, ADHD, or personality disorder. Comorbidities: anxiety disorders (~75%), substance use disorders (~60%, especially alcohol and cannabis), ADHD (~20%), eating disorders, and medical conditions (cardiovascular, metabolic syndrome). Bipolar disorder is among the most disabling conditions globally, ranking in the top 10 causes of disability (WHO).

Neuroimaging: Increased amygdala volume (especially with illness progression), reduced prefrontal cortex volume and activity, white matter hyperintensities (especially periventricular). Functional: hyperdopaminergic state during mania (reduced D2 receptor availability); altered serotonin transporter binding; noradrenergic hyperactivity. Lithium's neuroprotective effects include: GSK-3beta inhibition (neurotrophic signalling), BDNF upregulation, inositol depletion, and antiapoptotic effects. Valproate: histone deacetylase inhibition, GABA potentiation, glutamate reduction. Antipsychotics: D2 blockade addresses hyperdopaminergia of mania. HPA axis hyperactivation and circadian rhythm disturbances are present across phases and worsen with episode burden. Mood stabilisers such as lithium and valproate help restore balance and protect the brain from the damaging effects of repeated episodes. Bipolar disorder is a brain-based condition that responds to medication and therapy; it is not a character flaw.

Diagnosis is clinical and requires a comprehensive longitudinal assessment. Key components: detailed mood history across lifetime (manic, hypomanic, depressive episodes); onset, duration, triggers, severity of each episode; family psychiatric history; treatment history. Mental status during manic episode: elevated/irritable mood, pressured speech, grandiosity, decreased sleep need, flight of ideas, distractibility, goal-directed activity, poor judgment. Rating scales: Young Mania Rating Scale (YMRS) for mania severity; MADRS or HAM-D for depression severity; MDQ (Mood Disorder Questionnaire) for bipolar screening. Physical exam: thyroid function, toxicology screen (substance use can trigger episodes), neurological assessment.

Bipolar I Disorder (DSM-5-TR): At least one lifetime manic episode (>=7 days, or any duration if hospitalisation required or psychotic features present); major depressive episodes and hypomanic episodes may also be present but are not required for diagnosis. Bipolar II Disorder: At least one hypomanic episode AND at least one major depressive episode; no lifetime manic episodes. Cyclothymic Disorder: >=2 years (1 year in children) of numerous periods of hypomanic and depressive symptoms that do not meet full episode criteria; not symptom-free for >=2 months. Specifiers: With anxious distress; With mixed features; With rapid cycling; With melancholic/atypical/psychotic features; With peripartum onset; With seasonal pattern. ICD-11: Bipolar type I (6A60), Bipolar type II (6A61), Cyclothymic disorder (6A62).

SCID-5 or MINI for structured diagnostic interview. MDQ (Mood Disorder Questionnaire): 13-item screening questionnaire; sensitivity ~0.73, specificity ~0.90 for Bipolar I/II. HCL-32 (Hypomania Checklist): more sensitive for soft bipolar spectrum. YMRS: clinician-rated 11-item scale for manic symptom severity (standard in clinical trials). Life Chart: longitudinal graphical record of mood episodes, medications, and life events - essential for pattern recognition. Labs: thyroid function, lithium levels (if prescribed), metabolic panel, urinalysis; EEG if seizure history; neuroimaging if atypical features or first episode after age 50.

MDD: most critical distinction; ~40% of bipolar patients are initially diagnosed with unipolar MDD; ask specifically about past hypomanic/manic periods. ADHD: overlapping symptoms (distractibility, impulsivity, increased activity); ADHD symptoms are chronic and stable, not episodic.

Borderline Personality Disorder: emotional dysregulation and impulsivity overlap; BPD mood shifts are typically reactive to interpersonal stressors and last hours rather than days. Schizophrenia/schizoaffective disorder: psychotic features in both; mood episodes are central in bipolar; psychosis persists outside mood episodes in schizophrenia. Substance use disorders: stimulants, alcohol, cannabis, and cocaine can trigger manic-like states. Medical: hyperthyroidism, multiple sclerosis, CNS tumours can produce manic symptoms.

Treatment of Bipolar Disorder requires lifelong management with mood stabilisers as the cornerstone, supplemented by psychotherapy and psychosocial support. Treatment goals include acute episode management, relapse prevention, and functional recovery. Major guidelines (APA, NICE CG185, CANMAT/ISBD 2023) provide evidence-based recommendations; Kaplan & Sadock's Comprehensive Textbook supplements with combination strategies and treatment-resistant approaches. APA Practice Guideline (Bipolar Disorder, 2nd ed.) The APA recommends establishing a therapeutic alliance, monitoring psychiatric status, providing patient education, enhancing treatment adherence, promoting regular sleep patterns, and identifying new episodes early. For acute manic or mixed episodes: first-line pharmacological treatment involves lithium plus an antipsychotic, or valproate plus an antipsychotic. For less severe mania, monotherapy with lithium, valproate, or an atypical antipsychotic (olanzapine, risperidone) may suffice. Atypical antipsychotics are preferred over typical antipsychotics due to better side effect profiles. Antidepressants should be tapered in manic presentations; never use antidepressant monotherapy in bipolar disorder. NICE Guideline CG185 (Bipolar Disorder: Assessment and Management, updated 2023) Managing mania or hypomania: Ensure access to calming environments and reduced stimulation. If not on an antipsychotic or mood stabiliser, offer haloperidol, olanzapine, quetiapine, or risperidone. If first antipsychotic poorly tolerated or ineffective at maximum dose, offer an alternative from this list. If alternative antipsychotic insufficient, consider adding lithium. If lithium ineffective or not suitable (e.g. refuses blood monitoring), consider adding valproate - follow MHRA safety measures (see Valproate Safety below). If already on lithium, check plasma level and optimise; consider adding an antipsychotic. If already on mood stabiliser, consider increasing dose up to maximum BNF level; if no improvement, add antipsychotic. For mixed affective state, treat as mania and monitor closely for emergence of depression. Do not offer lamotrigine to treat mania. ECT is recommended for severe or prolonged manic episodes when other treatments have not worked or the condition is life-threatening. Managing bipolar depression: Offer psychological intervention developed for bipolar disorder (e.g. CBT, interpersonal therapy, behavioural couples therapy) or in line with NICE depression guidance. For moderate or severe bipolar depression not on medication: offer fluoxetine combined with olanzapine, or quetiapine monotherapy; if person prefers, consider olanzapine alone or lamotrigine alone.

If no response to fluoxetine-olanzapine or quetiapine, consider lamotrigine. If already on lithium: optimise level; if inadequate, add fluoxetine-olanzapine or quetiapine; alternatives include adding olanzapine or lamotrigine. If already on valproate: optimise dose; if limited response at maximum, add fluoxetine-olanzapine or quetiapine; alternatives include adding olanzapine or lamotrigine or changing treatment. Consider toxicity in overdose when prescribing during high suicide risk; limit quantity supplied. Within 4 weeks of symptom resolution, discuss continuation versus long-term treatment. Long-term management: After each episode, discuss longer-term management. Offer family intervention and structured psychological intervention (individual, group, or family) designed for bipolar disorder to prevent relapse. Long-term medication options include lithium, olanzapine, quetiapine, or valproate; choice depends on phase of illness, patient preference, and tolerability. Lithium has unique anti-suicidal effect and remains first choice for maintenance where clinically appropriate. CANMAT/ISBD Guidelines (2023 Update) The Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) guidelines rank treatments into first-, second-, and third-line options for acute mania, acute depression, and maintenance, based on efficacy, safety, tolerability, and risk of treatment-emergent affective switch. Acute Mania (CANMAT first-line): Lithium, divalproex, asenapine, aripiprazole, cariprazine, haloperidol, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone. Second-line: carbamazepine, lithium + divalproex, lithium + antipsychotic, divalproex + antipsychotic. Third-line: clozapine, ECT, adjunctive benzodiazepines. Acute Bipolar Depression (CANMAT first-line): Quetiapine, lurasidone, lumateperone; lithium; lamotrigine (bipolar II); lurasidone + lithium/divalproex. Second-line: cariprazine; lithium + lamotrigine; modafinil/armodafinil adjunct; olanzapine-fluoxetine combination; quetiapine + lithium/divalproex. Third-line: ECT; ketamine/esketamine; lithium + quetiapine; pramipexole adjunct; transcranial magnetic stimulation. Maintenance (CANMAT first-line): Aripiprazole, lithium, quetiapine, divalproex; lamotrigine (especially for bipolar II or depression-predominant). Second-line: asenapine, cariprazine, lamotrigine + lithium, lithium + quetiapine, lurasidone, olanzapine, risperidone LAI, ziprasidone. Acute Mania: Pharmacological Treatment Lithium (target serum 0.8-1.0 mEq/L for acute mania), valproate/divalproex (loading possible for rapid effect), and atypical antipsychotics (olanzapine, risperidone, quetiapine, aripiprazole, cariprazine, asenapine) are first-line. Severe mania may require hospitalisation and combination therapy (e.g. lithium or valproate plus antipsychotic). Benzodiazepines (lorazepam) may be used short-term for agitation and insomnia. Antidepressants must be tapered or discontinued - they can trigger or worsen mania. Carbamazepine and oxcarbazepine are alternatives; carbamazepine requires monitoring for drug interactions and blood dyscrasias. Bipolar Depression: Pharmacological Treatment Quetiapine, lurasidone, and olanzapine-fluoxetine combination are first-line. Lamotrigine is effective for prevention of depressive episodes and as monotherapy in bipolar II; slow titration required (risk of Stevens-Johnson syndrome);

ineffective for acute mania. Lithium has antidepressant properties and reduces suicide risk. Cariprazine has FDA approval for bipolar depression. Antidepressant monotherapy is contraindicated; if used, always combine with a mood stabiliser to reduce switch risk. Modafinil/armodafinil may augment in some cases. Ketamine/esketamine shows promise for treatment-resistant bipolar depression but remains off-label. Maintenance and Relapse Prevention Lithium remains the gold standard for long-term mood stabilisation; it has a unique anti-suicidal effect (meta-analyses suggest ~80% reduction in suicide compared to untreated bipolar). Valproate, lamotrigine (especially for depression prevention), and atypical antipsychotics (quetiapine, aripiprazole, asenapine, lurasidone) are alternatives or adjuncts. Regular monitoring: lithium levels (every 3-6 months when stable), electrolytes, renal function (eGFR), thyroid function (TSH); valproate - liver function, platelets; antipsychotics - metabolic panel, weight. Long-acting injectable antipsychotics (risperidone, aripiprazole, paliperidone) improve adherence in non-adherent patients. Treatment-Resistant Bipolar Disorder (Kaplan & Sadock) Combination therapy is common in refractory cases. Lithium plus valproate: the BALANCE study (2010) showed the combination more effective than valproate monotherapy but not superior to lithium alone for maintenance; combination may help in rapid-cycling. Lithium plus carbamazepine: retrospective data support efficacy in rapid-cycling; monitor both drug levels; no increased neurotoxicity in combination. Lithium or valproate plus lamotrigine: lamotrigine effective for depressive phase maintenance; valproate doubles lamotrigine levels (reduce lamotrigine dose); carbamazepine reduces lamotrigine levels. Lithium or valproate plus antipsychotic: evidence supports augmentation with olanzapine, quetiapine, risperidone. Gabapentin, topiramate, oxcarbazepine: limited controlled evidence; topiramate may help with weight gain from other agents; gabapentin not shown effective in controlled trials but may help anxiety/agitation. Clozapine: option for treatment-resistant mania. Electroconvulsive Therapy (ECT) ECT is effective in acute manic and depressive episodes, especially with psychosis, catatonia, or life-threatening presentation. NICE recommends ECT when other treatments have not worked or the condition is life-threatening. Generally 6-12 treatments; bilateral or right unilateral placement. Contraindications: raised intracranial pressure; relative: recent myocardial infarction, cerebral aneurysm. When to Hospitalise Indications: imminent risk of harm to self or others; severe mania with poor judgment (reckless spending, sexual disinhibition); psychosis; inability to care for self; medical instability; need for detoxification (substance use). Involuntary admission may be necessary if person lacks capacity and meets statutory criteria. Crisis plan and advance directive should be developed when well. Valproate Safety (MHRA/NICE)

Valproate must not be started for the first time in people (male or female) under 55 unless two specialists independently document that no other effective or tolerated treatment exists, or reproductive risks do not apply. Women and girls of childbearing potential: valproate only if other options unsuitable and Pregnancy Prevention Programme in place - significant teratogenic risk (neural tube defects, developmental delay). Men: advise effective contraception (condoms plus partner contraception) during treatment and for 3 months after stopping; potential fertility risks. Monitor liver function and platelet count. Psychotherapy and Psychosocial Interventions Psychoeducation about the illness, medication adherence, sleep hygiene, and early warning sign recognition is essential. CBT for bipolar disorder reduces relapse and improves functioning. Interpersonal and social rhythm therapy (IPSRT) targets disruption of circadian rhythms and social routines that trigger episodes - evidence for relapse prevention. Family-focused therapy (FFT) reduces relapse and improves family communication. NICE recommends structured psychological intervention (individual, group, or family) designed for bipolar disorder to prevent relapse, including mood monitoring, relapse management planning, and problem-solving. Carer-focused education and support programmes should be offered. Lifestyle and Self-Management Regular sleep-wake schedules are critical; sleep disruption is a major trigger for mania. Avoidance of alcohol, cannabis, and stimulants. Stress management and regular exercise support mood stability. Mood charting (e.g. NICE Life Chart, eMoods app) helps identify patterns and early warning signs. Advise against making major decisions during mania or hypomania.

Bipolar disorder is a chronic, lifelong condition in most cases. Without treatment: ~90% experience recurrence. With optimal treatment: significant reduction in episode frequency and severity. Lithium reduces suicide risk by ~80% compared to untreated bipolar. Functional recovery: even between episodes, many individuals experience residual mood symptoms, cognitive impairment, and social difficulties. Rapid cycling, mixed episodes, and comorbid substance use predict poorer prognosis. Bipolar II is not 'milder' than Bipolar I - depression burden is substantial and suicide risk is high. Average duration of a major depressive episode in bipolar disorder is 13 weeks; mania averages 13 weeks. Recovery is possible with sustained treatment and self-management.

Suicide: lifetime risk ~25-50x general population; 25-50% of patients attempt suicide at least once; ~10-15% complete suicide. Substance use: extremely common (60% lifetime comorbidity with SUD), worsening prognosis. Psychosocial: impaired relationships, high divorce rates, occupational underachievement, financial crises (from manic spending). Cognitive: impairment in attention, memory, and executive function even between episodes; worsens with episode burden. Medical: metabolic syndrome (partly medication-related), obesity, cardiovascular disease. Legal consequences of manic behaviour (reckless driving, financial contracts, sexual indiscretions).

No proven primary prevention. Relapse prevention: medication adherence is the single most important factor; psychoeducation about prodromal warning signs enables early intervention; maintaining regular sleep schedules and daily routines (IPSRT principles); avoiding triggers (alcohol, cannabis, stimulants, sleep deprivation, excessive stress). Patient education: bipolar disorder is a medical, brain-based, lifelong condition; medication is usually required long-term; missing doses or stopping medications abruptly risks relapse; mood monitoring apps (e.g., eMoods) facilitate self-monitoring; family involvement and support are crucial; suicidal thoughts are a medical emergency.

Ancient: bipolar-like states described by Greek physicians; Aretaeus of Cappadocia described mania and melancholia as related. 19th century: Jean-Pierre Falret coined 'folie circulaire' (circular insanity, 1854); Kraepelin systematised manic-depressive insanity (1899). 20th century: The Leonhard/Perris distinction between unipolar and bipolar depression (1960s). Lithium: first used for gout, anti-manic properties discovered by John Cade (1949, Australia); FDA approved for mania (1970). Sodium valproate approved for mania (1995, USA). DSM-5 (2013) separated bipolar disorders into their own chapter.

Bipolar disorder remains heavily stigmatised, partly due to associations with erratic or dangerous behaviour. Public figures (Catherine Zeta-Jones, Mariah Carey, Kanye West, Carrie Fisher) have increased awareness. The 'creative madness' stereotype (many artists and writers with bipolar) is partially supported by research but dangerously romanticises a serious illness. Over-diagnosis as a 'trendy' diagnosis and under-diagnosis as MDD or BPD both remain significant clinical problems. The term 'manic-depressive' remains in common use and ICD-10 still uses this terminology.

Lithium pharmacogenomics: biomarkers predicting lithium response (GWAS of response phenotypes). Ketamine/esketamine for bipolar depression. Cariprazine and other new-generation antipsychotics with specific bipolar depression data. Digital phenotyping: smartphone-based passive monitoring of circadian rhythms, speech, and activity patterns as early warning systems. Neuroimaging: progressive brain changes with episode burden; neuroprotective effects of lithium confirmed in longitudinal studies. Biomarkers: BDNF, oxidative stress markers, and inflammatory cytokines as state markers. Childhood/adolescent bipolar: diagnostic boundaries and treatment approach remain controversial.

APA. (2022). DSM-5-TR. APA Publishing. APA. Practice Guideline for the Treatment of Patients With Bipolar Disorder (2nd ed.). APA. NICE. (2023). Bipolar disorder: assessment and management. NICE guideline CG185. Yatham LN, et al. (2018). CANMAT and ISBD 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 20(2):97-170. 2023 update: Focus. 2023. Sadock BJ, Sadock VA, Ruiz P. (Eds.). (2024).

Kaplan & Sadock's Comprehensive Textbook of Psychiatry (11th ed.). Wolters Kluwer. StatPearls. Bipolar Disorder. NCBI Bookshelf NBK558998.

StatPearls: https://www.ncbi.nlm.nih.gov/books/NBK558998/ NICE CG185: https://www.nice.org.uk/guidance/cg185 NIMH Bipolar: https://www.nimh.nih.gov/health/topics/bipolar-disorder IBPF (International Bipolar Foundation): https://ibpf.org Depression and Bipolar Support Alliance: https://www.dbsalliance.org CANMAT: https://www.canmat.org Note: Educational only. Not a substitute for professional care.